Ptc Therapeutics Cmn (PTCT) 11.78 $PTCT You Can
Post# of 273272
Posted On: 09/27/2016 3:35:24 PM
Ptc Therapeutics Cmn (PTCT) 11.78 $PTCT
You Can’t Ignore the Biotech Breakout
Greg Guenthner - Daily Reckoning - Tue Sep 20, 8:46AM CDT
This post You Can’t Ignore the Biotech Breakout appeared first on Daily Reckoning . The major averages couldn’t hold onto their morning gains yesterday. Stocks spent the day slowly sinking into the red. But that didn’t stop a surprise FDA...
XBI: 68.37 (+0.60), SRPT: 58.54 (-1.12), PTCT: 11.78 (+0.14)
Advancing Preclinical Autoimmune Studies & Accelerated FDA Approvals Producing Rewards in Biotech Sector
PR Newswire - Tue Sep 20, 7:30AM CDT
Biotech & Pharma companies aim to create enhanced treatments & therapies for autoimmune diseases such as arthritis, cancer and other rare disease conditions through the latest preclinical studies, seeking accelerated FDA approvals and protocol assessments that include advancements from Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Regen BioPharma Inc. (OTCBB: RGBP), Novavax, Inc. (NASDAQ: NVAX), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Array BioPharma (NASDAQ: ARRY).
NVAX: 2.22 (-0.13), SRPT: 58.54 (-1.12), PTCT: 11.78 (+0.14), ARRY: 6.54 (-0.07)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Mon Sep 12, 3:30PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 8, 2016 it approved non-statutory stock options to purchase an aggregate of 22,900 shares of its common stock to eleven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 11.78 (+0.14)
PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website
PR Newswire - Wed Sep 07, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2016 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the Duchenne muscular dystrophy (DMD) community. The announcement is made as the international DMD community marks World Duchenne Awareness Day.
PTCT: 11.78 (+0.14)
Research Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century
PR Newswire - Mon Aug 22, 6:50AM CDT
Stock-Callers.com today has issued research reports on PTC Therapeutics Inc. (NASDAQ: PTCT), Grifols S.A. (NASDAQ: GRFS), Puma Biotechnology Inc. (NYSE: PBYI), and 22nd Century Group Inc. (NYSE MKT: XXII). These stocks belong in the Biotech arena, which over the recent weeks has slowly started to bounce back. In the past three months, the NASDAQ Biotech Index has risen 12%, while the S&P 500 has gained 6.9%. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
XXII: 1.24 (+0.08), PTCT: 11.78 (+0.14), GRFS: 16.11 (+0.14), PBYI: 69.82 (+0.14)
PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Thu Aug 04, 3:05PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2016.
PTCT: 11.78 (+0.14)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 6.03 (+0.16), BIIB: 314.10 (+4.28), VVUS: 1.18 (-0.06), PTCT: 11.78 (+0.14)
New Analyses from Phase 3 Study 009 of Translarna(TM) (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference
PR Newswire - Fri Jun 10, 9:30AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week 009 trial of Translarna(TM) (ataluren) for the treatment of nonsense mutation cystic fibrosis (caused by at least one nonsense mutation) are being presented at the 39th European Cystic Fibrosis Conference, June 8-11, 2016, in Basel, Switzerland.
PTCT: 11.78 (+0.14)
PTC Therapeutics Announces Winners of the Global Cystic Fibrosis Patient Group Awards
PR Newswire - Mon May 16, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the cystic fibrosis (CF) community. The announcement coincides with National Cystic Fibrosis Awareness Month celebrated throughout the month of May.
PTCT: 11.78 (+0.14)
PTC Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 5:06PM CDT
SOUTH PLAINFIELD, N.J. (AP) _ PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $41.2 million in its first quarter.
PTCT: 11.78 (+0.14)
PTC Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Thu May 05, 3:01PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2016.
PTCT: 11.78 (+0.14)
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
PR Newswire - Mon May 02, 10:25AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PTCT: 11.78 (+0.14)
PTC 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against PTC Therapeutics, Inc. - PTCT
GlobeNewswire - Fri Apr 29, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until May 2, 2016 to file lead plaintiff applications in a securities class action lawsuit against PTC Therapeutics, Inc. (Nasdaq
TCT). Investor losses must relate to purchases of the Company's securities between May 6, 2014 and February 29, 2016. This action is pending in the United States District Court for the District of New Jersey.
PTCT: 11.78 (+0.14)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PTC Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - PTCT
ACCESSWIRE - Fri Apr 29, 6:08PM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against PTC Therapeutics, Inc. ("PTC Therapeutics" or the "Company" (NASDAQ: PTCT) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased PTC Therapeutics securities between May 6, 2014 and February 23, 2016 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
PTCT: 11.78 (+0.14)
ALERT: Rosen Law Firm Reminds PTC Therapeutics, Inc. Investors of Important May 2 Deadline in Class Action - PTCT
GlobeNewswire - Thu Apr 28, 5:04PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of PTC Therapeutics, Inc. securities (NASDAQ TCT) from May 6, 2014 through February 23, 2016, all dates inclusive (the "Class Period" of the important May 2, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for PTC Therapeutics investors under the federal securities laws.
PTCT: 11.78 (+0.14)
Final Reminder for PTC Therapeutics, Inc. Shareholders - May 2, 2016 Deadline
ACCESSWIRE - Thu Apr 28, 3:42PM CDT
RADNOR, PA / ACCESSWIRE / April 28, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a shareholder class action lawsuit has been filed against PTC Therapeutics, Inc. (Nasdaq: PTCT) ("PTC" or the "Company" on behalf of purchasers of the Company's securities between May 6, 2014 and February 29, 2016, inclusive (the "Class Period" .
PTCT: 11.78 (+0.14)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Involving PTC Therapeutics, Inc. and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
GlobeNewswire - Thu Apr 28, 11:55AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PTC Therapeutics, Inc. (NASDAQ TCT) securities between May 7, 2014 and February 29, 2016.
PTCT: 11.78 (+0.14)
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
GlobeNewswire - Wed Apr 27, 11:19AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PTCT: 11.78 (+0.14)
PTC Therapeutics Appoints Dr. Tuyen Ong as Chief Medical Officer
PR Newswire - Tue Apr 26, 3:01PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tuyen Ong, M.D. has been promoted to Chief Medical Officer. Dr. Ong joined PTC in 2014 as the Senior Vice President, Head of Clinical Development and Translational Research. He succeeds Robert J. Spiegel M.D., FACP, who has served as PTC's Chief Medical Officer since 2011. Dr. Spiegel will remain active in a consulting role, continuing to support PTC's development programs and its global clinical and regulatory activities.
PTCT: 11.78 (+0.14)
You Can’t Ignore the Biotech Breakout
Greg Guenthner - Daily Reckoning - Tue Sep 20, 8:46AM CDT
This post You Can’t Ignore the Biotech Breakout appeared first on Daily Reckoning . The major averages couldn’t hold onto their morning gains yesterday. Stocks spent the day slowly sinking into the red. But that didn’t stop a surprise FDA...
XBI: 68.37 (+0.60), SRPT: 58.54 (-1.12), PTCT: 11.78 (+0.14)
Advancing Preclinical Autoimmune Studies & Accelerated FDA Approvals Producing Rewards in Biotech Sector
PR Newswire - Tue Sep 20, 7:30AM CDT
Biotech & Pharma companies aim to create enhanced treatments & therapies for autoimmune diseases such as arthritis, cancer and other rare disease conditions through the latest preclinical studies, seeking accelerated FDA approvals and protocol assessments that include advancements from Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Regen BioPharma Inc. (OTCBB: RGBP), Novavax, Inc. (NASDAQ: NVAX), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Array BioPharma (NASDAQ: ARRY).
NVAX: 2.22 (-0.13), SRPT: 58.54 (-1.12), PTCT: 11.78 (+0.14), ARRY: 6.54 (-0.07)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Mon Sep 12, 3:30PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 8, 2016 it approved non-statutory stock options to purchase an aggregate of 22,900 shares of its common stock to eleven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 11.78 (+0.14)
PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website
PR Newswire - Wed Sep 07, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2016 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the Duchenne muscular dystrophy (DMD) community. The announcement is made as the international DMD community marks World Duchenne Awareness Day.
PTCT: 11.78 (+0.14)
Research Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century
PR Newswire - Mon Aug 22, 6:50AM CDT
Stock-Callers.com today has issued research reports on PTC Therapeutics Inc. (NASDAQ: PTCT), Grifols S.A. (NASDAQ: GRFS), Puma Biotechnology Inc. (NYSE: PBYI), and 22nd Century Group Inc. (NYSE MKT: XXII). These stocks belong in the Biotech arena, which over the recent weeks has slowly started to bounce back. In the past three months, the NASDAQ Biotech Index has risen 12%, while the S&P 500 has gained 6.9%. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
XXII: 1.24 (+0.08), PTCT: 11.78 (+0.14), GRFS: 16.11 (+0.14), PBYI: 69.82 (+0.14)
PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Thu Aug 04, 3:05PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2016.
PTCT: 11.78 (+0.14)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 6.03 (+0.16), BIIB: 314.10 (+4.28), VVUS: 1.18 (-0.06), PTCT: 11.78 (+0.14)
New Analyses from Phase 3 Study 009 of Translarna(TM) (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference
PR Newswire - Fri Jun 10, 9:30AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week 009 trial of Translarna(TM) (ataluren) for the treatment of nonsense mutation cystic fibrosis (caused by at least one nonsense mutation) are being presented at the 39th European Cystic Fibrosis Conference, June 8-11, 2016, in Basel, Switzerland.
PTCT: 11.78 (+0.14)
PTC Therapeutics Announces Winners of the Global Cystic Fibrosis Patient Group Awards
PR Newswire - Mon May 16, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the cystic fibrosis (CF) community. The announcement coincides with National Cystic Fibrosis Awareness Month celebrated throughout the month of May.
PTCT: 11.78 (+0.14)
PTC Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 5:06PM CDT
SOUTH PLAINFIELD, N.J. (AP) _ PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $41.2 million in its first quarter.
PTCT: 11.78 (+0.14)
PTC Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Thu May 05, 3:01PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2016.
PTCT: 11.78 (+0.14)
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
PR Newswire - Mon May 02, 10:25AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PTCT: 11.78 (+0.14)
PTC 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against PTC Therapeutics, Inc. - PTCT
GlobeNewswire - Fri Apr 29, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until May 2, 2016 to file lead plaintiff applications in a securities class action lawsuit against PTC Therapeutics, Inc. (Nasdaq TCT). Investor losses must relate to purchases of the Company's securities between May 6, 2014 and February 29, 2016. This action is pending in the United States District Court for the District of New Jersey. PTCT: 11.78 (+0.14)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PTC Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - PTCT
ACCESSWIRE - Fri Apr 29, 6:08PM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against PTC Therapeutics, Inc. ("PTC Therapeutics" or the "Company"
(NASDAQ: PTCT) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased PTC Therapeutics securities between May 6, 2014 and February 23, 2016 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . PTCT: 11.78 (+0.14)
ALERT: Rosen Law Firm Reminds PTC Therapeutics, Inc. Investors of Important May 2 Deadline in Class Action - PTCT
GlobeNewswire - Thu Apr 28, 5:04PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of PTC Therapeutics, Inc. securities (NASDAQ
TCT) from May 6, 2014 through February 23, 2016, all dates inclusive (the "Class Period" of the important May 2, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for PTC Therapeutics investors under the federal securities laws. PTCT: 11.78 (+0.14)
Final Reminder for PTC Therapeutics, Inc. Shareholders - May 2, 2016 Deadline
ACCESSWIRE - Thu Apr 28, 3:42PM CDT
RADNOR, PA / ACCESSWIRE / April 28, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a shareholder class action lawsuit has been filed against PTC Therapeutics, Inc. (Nasdaq: PTCT) ("PTC" or the "Company"
on behalf of purchasers of the Company's securities between May 6, 2014 and February 29, 2016, inclusive (the "Class Period" . PTCT: 11.78 (+0.14)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Involving PTC Therapeutics, Inc. and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
GlobeNewswire - Thu Apr 28, 11:55AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PTC Therapeutics, Inc. (NASDAQ
TCT) securities between May 7, 2014 and February 29, 2016. PTCT: 11.78 (+0.14)
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
GlobeNewswire - Wed Apr 27, 11:19AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PTCT: 11.78 (+0.14)
PTC Therapeutics Appoints Dr. Tuyen Ong as Chief Medical Officer
PR Newswire - Tue Apr 26, 3:01PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tuyen Ong, M.D. has been promoted to Chief Medical Officer. Dr. Ong joined PTC in 2014 as the Senior Vice President, Head of Clinical Development and Translational Research. He succeeds Robert J. Spiegel M.D., FACP, who has served as PTC's Chief Medical Officer since 2011. Dr. Spiegel will remain active in a consulting role, continuing to support PTC's development programs and its global clinical and regulatory activities.
PTCT: 11.78 (+0.14)
(0)
(0)Scroll down for more posts ▼